Kiril Poukalov

Postdoc @UTSWMedCenter
Gene Editing

[Kiril Poukalov @KPoukalov]

@JMTali Great work Charlie and Mathew! It looks like in some of the mutants and shuffle variants there is greater neurite enrichment (in Trak2 atleast), do you think some of these localization elements can be optimized to localize better?

[Kiril Poukalov @KPoukalov]

@TheKoshurDoc We need to know the cerebrospinal pressure during the movement too. If I recall correctly, pressure is transferred in valsalva during exercise.

[Kiril Poukalov @KPoukalov]

@endless_frank put out some peanuts and they'll never leave

[Kiril Poukalov @KPoukalov]

@techinvestoor @whitelightfrom @Allan_Reine @davidrliu good luck with your investment, I hope for the sake of the patients that it works outs.

[Kiril Poukalov @KPoukalov]

@techinvestoor @whitelightfrom @Allan_Reine @davidrliu Targeted delivery is my field, progress is not being made "just fine"

[Kiril Poukalov @KPoukalov]

@whitelightfrom @techinvestoor @Allan_Reine @davidrliu Exactly, extrahepatic delivery is key for all these gene editing companies and none of them have anything close to a solution. The market for liver diseases is very small and they're all fighting over it.

[Kiril Poukalov @KPoukalov]

@techinvestoor Good Luck

[Kiril Poukalov @KPoukalov]

@techinvestoor @whitelightfrom @Allan_Reine @davidrliu You're overestimating where they're at with this tech.

[Kiril Poukalov @KPoukalov]

@Biotech2k1 All these CRISPR companies are hopeless until one has efficient extra-hepatic non-viral delivery.

[Kiril Poukalov @KPoukalov]

@zhaoweiasu Convoluted and biased explanation.

[Kiril Poukalov @KPoukalov]

@Biotech2k1 @biosleuth I am a scientist. No one can predict the reaction to a vector because their mechanisms are varied and not well understood.

[Kiril Poukalov @KPoukalov]

@Biotech2k1 @biosleuth It's not and you can't because no one can.

[Kiril Poukalov @KPoukalov]

@Biotech2k1 The big limitation is delivery, that's why all these companies are floundering trying to target the same handful of liver diseases. Profiling off-target editing is straightforward and new editors are higher fidelity.

[Kiril Poukalov @KPoukalov]

@Biotech2k1 The technology for in-vivo gene editing simply doesn't exist for any tissue besides liver. But that won't be the case in 5 years.

[Eric N. Olson @Transactivator]

Happy Halloween from the Olson Lab! @UTSWMedCenter

[Kiril Poukalov @KPoukalov]

@Biotech2k1 The expansion of M2 in 2020 was much greater than at any other point in the past 60 years. It definitely contributed to inflation but that's not to say inflation will return after rate cuts.

[Kiril Poukalov @KPoukalov]

@Biotech2k1 👍

[Kiril Poukalov @KPoukalov]

Happy to announce my PhD work is published!🎉
@PNASNews : Myospreader improves gene editing in skeletal muscle by myonuclear propagation https://t.co/aRISKubvtH

[Collin Douglas @CollinDouglas13]

So excited to finally see this work published! 🙌

#PLOSONE: An optimized approach to study nanoscale sarcomere structure utilizing super-resolution microscopy ... https://t.co/JshkJ9aTpw

#myotwitter

[Kiril Poukalov @KPoukalov]

@CollinDouglas13 Really nice work Collin! looking forward to using this